| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | IGKC |
| Uniprot No | P01834 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-236aa |
| 氨基酸序列 | METPAQLLFLLLLWLPDSTGENVLTQSPGTLSLSPGERATLSCRASQSLSSSYLAWYQQKPGQAPRLLIYGVSSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGTSRPITFGQGTRLDIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC |
| 分子量 | 51.7 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人IGKC蛋白的3-4条参考文献示例(文献为假设性描述，仅供参考)：
---
### 1. **"Recombinant expression and functional analysis of human immunoglobulin kappa constant (IGKC) in antibody assembly"**
**作者**: Smith A, et al.
**摘要**：本研究构建了人源IGKC蛋白的重组表达系统，利用CHO细胞实现高效表达，证明IGKC与重链的协同表达可显著提升完整抗体的组装效率，为单克隆抗体生产优化提供了新策略。
---
### 2. **"Structural insights into human IGKC and its role in antigen recognition"**
**作者**: Chen L, et al.
**摘要**：通过X射线晶体学解析了重组人IGKC蛋白的三维结构，揭示了其恒定区构象对轻链-重链相互作用的关键影响，为基于结构的抗体工程改造提供了理论依据。
---
### 3. **"IGKC as a biomarker in cancer immunotherapy: Recombinant production and clinical validation"**
**作者**: Johnson R, et al.
**摘要**：开发了重组人IGKC蛋白的体外检测方法，证实其在多种癌症患者血清中显著高表达，提示其作为免疫治疗疗效预测标志物的潜力。
---
### 4. **"Optimizing recombinant IGKC expression in yeast for high-throughput antibody screening"**
**作者**: Kim J, et al.
**摘要**：优化了毕赤酵母系统表达重组人IGKC蛋白的条件，实现了可溶性高产量表达，并验证其在噬菌体展示技术中筛选高亲和力抗体的应用价值。
---
注：以上文献为模拟内容，实际引用需查阅PubMed、Web of Science等数据库获取真实发表的论文。
Recombinant human IGKC protein refers to the engineered form of the immunoglobulin kappa constant chain, a critical component of antibodies in the human immune system. IGKC is a conserved region of the antibody’s light chain, pairing with the variable domain to stabilize immunoglobulin structure and mediate antigen recognition. As part of the kappa light chain, IGKC is expressed in approximately 60% of human antibodies, working with heavy chains to form functional antigen-binding regions.
The recombinant version is produced using biotechnological methods, such as expression in mammalian (e.g., CHO cells) or bacterial systems (e.g., E. coli), followed by purification. This bypasses the need for plasma extraction, ensuring scalability and reducing batch variability. Its production often involves codon optimization, promoter selection, and fusion tags to enhance solubility and yield. Challenges include maintaining proper folding and disulfide bond formation, which are essential for functionality.
Recombinant IGKC has broad applications. In research, it serves as a tool to study B-cell development, antibody assembly, and immune dysregulation. Clinically, it is used in diagnostic assays to detect immune disorders, monitor monoclonal gammopathies, or validate therapeutic antibody quality. In drug development, it aids in engineering bispecific antibodies or optimizing antibody fragments for targeted therapies. Quality control involves rigorous testing for endotoxin levels, purity, and binding activity to ensure consistency. By enabling precise manipulation of antibody components, recombinant IGKC accelerates biomedical discoveries and therapeutic innovation.
×
